Mechanisms of AS01B Adjuvant in CD4 T Cell Activation

AS01B adjuvant mechanisms and CD4 T cell responses

AS01B induces robust and durable CD4 T cell responses via a two-phase mechanism of transient inflammatory cytokine induction followed by sustained IFN-signaling pathway activation that drives context-dependent Th1 or Th2 polarization.

Abstract

AS01B adjuvant induces CD4 T cell responses through a two-phase mechanism involving initial transient inflammatory activation followed by sustained IFN-signaling pathway engagement. Studies demonstrate that AS01B triggers early innate responses including IL-6 and CRP peaking at 24 hours post-vaccination, followed by IFN-γ upregulation and activation of IFN-inducible genes (STAT1, IRF1, MX1, CXCL10) after the second dose. This innate activation directly correlates with enhanced CD4+ T cell outcomes, as multi-parametric modeling shows associations between CRP, IL-6, IFN-signaling pathway activation and subsequent CD4 responses. AS01B consistently induces superior CD4 T cell responses compared to AS02A (3.1-fold higher frequencies), AS03 (5.4-fold higher), AS04 (2.8-fold higher), and aluminum adjuvants, with exceptional durability extending 18-36+ months post-vaccination.

The CD4 response polarization induced by AS01B is context-dependent rather than fixed. Protein/AS01B formulations activate PPAR, FcεRI, and TGF-β pathways, inducing Th2/Tfh2-biased responses that correlate with enhanced antibody production and memory B cell frequencies. In contrast, most other AS01B formulations primarily activate IFN-signaling pathways, driving strong Th1 responses characterized by high IFN-γ production. AS01B’s superiority depends on both liposomal delivery and optimal component dosing, as AS01E containing half the MPL/QS-21 produces comparable innate profiles but 2.2-fold lower CD4 responses. The synergistic combination of MPL and QS-21 in liposomes appears critical for maximal CD4 activation.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200

• Papers screened using: AS01B Adjuvant Focus, CD4 T Cell Response Measurement, Appropriate Study Type, AS01B Data Availability, CD4 T Cell Data Inclusion, CD4 T Cell Response Focus, AS01B Effect Attribution, Full Publication Status

• n = 200 Papers screened out

• n = 190 Papers included for extraction

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex. We ran this query: “AS01B adjuvant mechanisms and CD4 T cell responses” and retrieved 200 papers most relevant.

Screening

We screened in sources based on abstracts that met key criteria:

• AS01B Adjuvant Focus: Investigates AS01B adjuvant specifically.
• CD4 T Cell Response Measurement: Measures CD4 T cell responses as primary or secondary outcomes.
• Appropriate Study Type: Human clinical trial or established animal study.
• AS01B Data Availability: Includes AS01B data.
• CD4 T Cell Data Inclusion: Includes CD4 T cell data.
• CD4 T Cell Response Focus: Focuses on CD4 T cell response data.
• AS01B Effect Attribution: Specific attribution of AS01B adjuvant effects.
• Full Publication Status: Full-text publication.

All screening questions were considered to make judgments on screening in each paper.

Data extraction

We asked a large language model to extract each data column below from each paper.

• Study Context: Key study design information relevant to AS01B adjuvant mechanisms.
• AS01B Mechanisms: Mechanistic data showing how AS01B works at the innate immunity level.
• CD4 Responses: CD4 T cell response data specifically for AS01B.
• Mechanism-Response Links: Evidence connecting AS01B mechanisms to CD4 T cell responses.
• Adjuvant Comparisons: Comparative data between AS01B and other adjuvants.
• Key Findings: Main conclusions and key findings about AS01B adjuvant mechanisms.

Results

Characteristics of included studies

AS01B mechanisms at the innate immunity level

AS01B consistently induced IFN-γ production across multiple studies. Burny et al. demonstrated that AS01B induced transient innate responses including IL-6 and CRP, which peaked at 24 hours post-vaccination. After the second injection, AS01B increased IFN-γ levels and upregulated IFN-inducible genes suggesting AS01B may activate both Th1-associated and Th2-associated pathways based on context.

CD4 T cell responses induced by AS01B

AS01B consistently induced robust CD4 T cell responses across diverse antigens and species, demonstrating exceptional durability of CD4 responses. It also revealed context-dependent Th1/Th2 skewing with stronger responses generally favoring Th1.

Comparative adjuvant effects

Mechanistic links between AS01B activation and CD4 T cell responses

The evidence reveals AS01B functions through a two-phase mechanism linking innate activation to durable CD4 responses. Transient inflammatory mediators (IL-6, CRP) peak shortly after vaccination, followed by delayed activation of the IFN-signaling pathway after the second dose. This dual-phase process drives robust CD4 T cell responses characterized by high magnitude, extended durability, and context-dependent polarization. AS01B’s unique formulation plays a critical role in enhancing vaccine immunogenicity through complementary mechanisms for T cell activation.